ROCHESTER, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)MARY M GOOLEY HEMOPHILIA CENTER INC, founded in 1959, is a mid-sized nonprofit that reported $25.4M in total revenue in fiscal year 2023. The organization ran a surplus of $5.5M, a strong 22% operating margin.
TO PROVIDE EDUCATION, TREATMENT, RESEARCH, ADVOCACY AND SUPPORTIVE PROGRAMS TO IMPROVE THE LIVES OF PEOPLE AFFECTED BY BLEEDING DISORDERS AND IRON OVERLOAD.
HOME INFUSION PROGRAM AND HEMOPHILIA COMPREHENSIVE CARE: THE CENTER HAS APPROXIMATELY 399 BLEEDING DISORDER PATIENTS ON ITS ACTIVE CASELOAD. IN 2023, 231 UNIQUE PATIENTS WITH HEMOPHILIA, VON...
HOME INFUSION PROGRAM AND HEMOPHILIA COMPREHENSIVE CARE: THE CENTER HAS APPROXIMATELY 399 BLEEDING DISORDER PATIENTS ON ITS ACTIVE CASELOAD. IN 2023, 231 UNIQUE PATIENTS WITH HEMOPHILIA, VON WILLEBRAND DISEASE AND OTHER RARE CLOTTING DEFICIENCIES WERE EVALUATED AND TREATED. 60 PATIENTS WITH MODERATE AND SEVERE HEMOPHILIA ATTEND SPECIALIZED COMPREHENSIVE CARE CLINICS AT LEAST ONCE EACH YEAR, RECEIVING CONSULTATION FROM AN ONSITE HEMATOLOGIST, NURSE COORDINATOR, SOCIAL WORKER, PHYSICAL THERAPIST, ORTHOPEDIC SURGEON AND DENTIST. THE CENTER HAS AN ON-SITE SPECIALTY PHARMACY THAT PROVIDES CLOTTING FACTOR TO 53 HEMOPHILIA PATIENTS VIA OUR HOME INFUSION PROGRAM.
HEMOCHROMATOSIS AND IRON OVERLOAD DISORDER ACTIVITIES: THE CENTER PROVIDES SPECIALIZED EVALUATION AND CARE FOR PATIENTS WITH HEREDITARY HEMOCHROMATOSIS AND IRON OVERLOAD. TYPICALLY, PATIENTS WITH...
HEMOCHROMATOSIS AND IRON OVERLOAD DISORDER ACTIVITIES: THE CENTER PROVIDES SPECIALIZED EVALUATION AND CARE FOR PATIENTS WITH HEREDITARY HEMOCHROMATOSIS AND IRON OVERLOAD. TYPICALLY, PATIENTS WITH THESE CONDITIONS RECEIVE REGULAR THERAPEUTIC PHLEBOTOMIES TO DIMINISH EXCESS IRON STORED IN THEIR BODIES, DIMINISHING RISK OF PERMANENT ORGAN DAMAGE. THE CENTER SERVES APPROXIMATELY 230 HEMOCHROMATOSIS/IOD PATIENTS.
BLEEDING DISORDER AND HEMOCHROMATOSIS RESEARCH: THE CENTER HAS BEEN ACTIVELY INVOLVED IN RESEARCH AND CLINICAL TRIALS IN AN EFFORT TO CULTIVATE ADVANCES IN HEMOPHILIA, VON WILLEBRAND DISEASE AND...
BLEEDING DISORDER AND HEMOCHROMATOSIS RESEARCH: THE CENTER HAS BEEN ACTIVELY INVOLVED IN RESEARCH AND CLINICAL TRIALS IN AN EFFORT TO CULTIVATE ADVANCES IN HEMOPHILIA, VON WILLEBRAND DISEASE AND HEMOCHROMATOSIS. IN 2023, THE CENTER PARTICIPATED IN 4 OPEN RESEARCH STUDIES ADDRESSING A WIDE RANGE OF CLINICAL AREAS AND OUTCOMES. IN ADDITION, THE CENTER WORKS CLOSELY WITH THE CENTER FOR DISEASE CONTROL (CDC) AND THE AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK (ATHN) REGISTRIES, COLLECTING DATA AS PART OF A NATIONAL EFFORT TO BETTER UNDERSTAND AND CARE FOR RARE BLEEDING DISORDERS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $25,362,099 | $23,562,520 | +0.1% |
| Expenses | $19,865,599 | $18,876,090 | +0.1% |
| Net Income | $5,496,500 | $4,686,430 | +0.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| AKUA ASANTE MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| KHARI SABB | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| RONALD SHAM MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| SAMANTHA VITAGLIANO DMD | CHAIRPERSON | 1.00 |
Officer
Director
|
$1,000 | $0 | $1,000 |
| DAN GURELL | TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| CHRISTINE HAY MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ANDREW PARK | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| LARRY DENK MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| PETER KOUIDES MD | NON-VOTING BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| GREGORY LIGHTHOUSE CPA | CFO | 40.00 |
Officer
|
$151,965 | $20,277 | $172,242 |
| THOMAS WILMARTH | PRESIDENT & CEO | 40.00 |
Officer
|
$206,914 | $34,791 | $241,705 |
| ERIC IGLEWSKI LMSW | VP OF CLINICAL SERVICES | 40.00 |
Highest
|
$133,994 | $21,619 | $155,613 |
| TARA VEITH MSN FNP-C | NURSE PRACTITIONER | 40.00 |
Highest
|
$104,780 | $5,636 | $110,416 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $25,362,099 | $19,865,599 | $28,705,288 | $5,496,500 |
| 2022 | $23,562,520 | $18,876,090 | $22,291,698 | $4,686,430 |
| 2021 | $23,643,261 | $19,271,866 | $16,939,861 | $4,371,395 |
| 2020 | $20,210,581 | $17,189,318 | $12,634,459 | $3,021,263 |
| 2019 | $21,245,539 | $18,856,026 | $9,571,034 | $2,389,513 |
| 2018 | $16,780,690 | $15,704,719 | $7,002,405 | $1,075,971 |
Compare MARY M GOOLEY HEMOPHILIA CENTER INC with other nonprofits in New York and across the country.